Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 525

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Age at disability milestones in multiple sclerosis

Confavreux, Christian, Vukusic, Sandra·2006·Brain
DOI 10.1093/brain/awh714
Open this paper in CoChat — free account

Abstract

Many efforts have been devoted to the description of the prognosis of multiple sclerosis and its possible influential factors in terms of time to reach disability milestones. By contrast, the age at which patients with multiple sclerosis reach these milestones has not yet stirred much interest. We have tested the hypothesis whether the prognosis of multiple sclerosis depends on the current age of patients and the initial course of the disease. We have assessed disease onset and course, and assignment of scores of irreversible disability in 1844 patients with multiple sclerosis. We have used three scores on the Kurtzke Disability Status Scale as benchmarks of disability accumulation: DSS 4 (limited walking but without aid), DSS 6 (walking with unilateral aid) and DSS 7 (wheelchair-bound). We used Kaplan-Meier analyses to estimate the age of the patients at assignment of disability milestones. The possible influence of the initial course of multiple sclerosis and of other clinical variables early assessable in the disease on these outcome measures was also studied, using the Kaplan-Meier curves for univariate analyses and Cox models for multivariate analyses. For the 1844 patients, median ages at time of assignment of irreversible disability were 44.3 years (95% CI 43.3-45.2) for a score of DSS 4, 54.7 years (95% CI 53.5-55.8) for DSS 6 and 63.1 years (95% CI 61.0-65.1) for DSS 7. These results were essentially similar whether the initial course of multiple sclerosis was exacerbating-remitting or progressive, and whatever the initial symptomatology. Females reached disability milestones at an older age than males. The most influential clinical factor was age at clinical onset of multiple sclerosis: the younger the onset, the younger the age at assignment of disability milestones. Therefore, prognosis in multiple sclerosis appears, at least to some extent, as age-dependent and not substantially affected by the initial course, be it exacerbating-remitting or progressive. Aside acute focal recurrent inflammation and diffuse chronic neurodegeneration, accelerated ageing-related mechanisms may operate in the central nervous system of multiple sclerosis patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awh714

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 53

  1. Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol Sci2000; 21 Suppl: 831–8. · DOI
  2. Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, Hartung HP, et al. European validation of a standardized clinical description of multiple sclerosis. J Neurol2004; 251: 1472–80. · DOI
  3. Broman T, Andersen O, Bergmann L. Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scand1981; 63: 6–33. · DOI
  4. Chari DM, Crang AJ, Blakemore WF. Decline in rate of colonization of oligodendrocyte progenitor cell (OPC)-depleted tissue by adult OPCs with age. J Neuropathol Exp Neurol2003; 62: 908–16. · DOI
  5. Clark VA, Detels R, Visscher BR, Valdiviezo NL, Malmgren RM, Dudley JP. Factors associated with a malignant or benign course of multiple sclerosis. J Am Med Assoc1982; 248: 856–60. · doi:10.1001/jama.1982.03330070044028
  6. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain1980; 103: 281–300. · DOI · Paper page
  7. Confavreux C, Darchy P, Alperovitch A, Aimard G, Devic M. Le sud-Est français, zone ‘à haut risque’ de Sclérose en Plaques? Presse Med1987; 16: 622–3.
  8. Confavreux C, Compston DAS, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European Database for Multiple Sclerosis. J Neurol Neurosurg Psychiatry1992; 55: 671–6. · DOI · Paper page
  9. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med2000; 343: 1430–8. · DOI · Paper page
  10. Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counseling and therapy. Curr Opin Neurol2002; 15: 257–66. · DOI
  11. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain2003; 126: 770–82. · DOI · Paper page
  12. Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain1999; 122: 625–39. · DOI · Paper page
  13. Detels R, Clark VA, Valdiviezo NL, Visscher BR, Malmgren RM, Dudley JP, et al. Factors associated with a rapid course of multiple sclerosis. Arch Neurol1982; 39: 337–41. · DOI
  14. Eriksson M, Andersen O, Runmarker B. Long-term follow-up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler2003; 9: 260–74. · DOI
  15. Filippi M, Wolinsky JS, Sormani MP, Comi G; European/Canadian Glatiramer Acetate Study Group. Enhancement frequency decreases with increasing age in relapsing-remitting multiple sclerosis. Neurology2001; 56: 422–3. · DOI
  16. Fraker PJ, Lill-Elghanian DA. The many roles of apoptosis in immunity as modified by aging and nutritional status. J Nutr Health Aging2004; 8: 56–63.
  17. Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, et al. and the Turkish Multiple Sclerosis Study Group (TUMSSG). Survival and predictors of disability in Turkish MS patients. Neurology1998; 51: 765–72. · DOI
  18. Kassubek J, Tumani H, Ecker D, Kurt A, Ludolph AC, Juengling FD. Age-related brain parenchymal fraction is significantly decreased in young multiple sclerosis patients: a quantitative MRI study. Neuroreport2003; 14: 427–30. · DOI
  19. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain1999; 122: 1941–50. · DOI
  20. Kurtzke JF. On the evaluation of disability in multiple sclerosis. Neurology1961; 11: 686–94. · DOI · Paper page
  21. Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD. Studies on natural history of multiple sclerosis. 4: Clinical features of the onset bout. Acta Neurol Scand1968; 44: 467–94. · DOI
  22. Kurtzke JF, Beebe GW, Nagler B, Nefzger MD, Auth TL, Kurland LT. Studies on the natural history of multiple sclerosis. V. Long-term survival in young men. Arch Neurol1970; 22: 215–25. · DOI
  23. Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD. Studies on the natural history of multiple sclerosis. 7: Correlates of clinical changes in an early bout. Acta Neurol Scand1973; 49: 379–95. · doi:10.1111/j.1600-0404.1973.tb01311.x
  24. Kurtzke JF, Beebe GW, Nagler B, Kurland LT, Auth TL. Studies on the natural history of multiple sclerosis—Early prognostic features of the later course of the illness. J Chronic Dis1977; 30: 819–30. · DOI
  25. Leibowitz U, Alter M, Halpern L. Clinical studies of multiple sclerosis in Israel. III. Clinical course and prognosis related to age at onset. Neurology1964a; 14: 926–32. · DOI
  26. Leibowitz U, Halpern L, Alter M. Clinical studies of multiple sclerosis in Israel. I. A clinical analysis based on a country-wide survey. Arch Neurol1964; 10: 502–12. · doi:10.1001/archneur.1964.00460170072011
  27. Leibowitz U, Alter M. Clinical factors associated with increased disability in multiple sclerosis. Acta Neurol Scand1970; 46: 53–70. · doi:10.1111/j.1600-0404.1970.tb05604.x
  28. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology1996; 46: 907–11. · DOI · Paper page
  29. McAlpine D, Compston N. Some aspects of the natural history of disseminated sclerosis: incidence, course and prognosis; factors affecting onset and course. Q J Med1952; 21: 135–67.
  30. Miller DH, Hornabrook RW, Purdie G. The natural history of multiple sclerosis: a regional study with some longitudinal data. J Neurol Neurosurg Psychiatry1992; 55: 341–6. · DOI
  31. Minderhoud JM, Van der Hoeven JH, Prange AJ. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand1988; 78: 10–5. · DOI
  32. Müller R. Course and prognosis of disseminated sclerosis in relation to age at onset. Arch Neurol Psychiatry1951; 66: 561–70. · doi:10.1001/archneurpsyc.1951.02320110026002
  33. Myhr KM, Riise T, Vedeler C, Nortvedt MW, Gronning R, Midgard R, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler2001; 7: 59–65. · DOI
  34. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med2000; 343: 938–52. · DOI · Paper page
  35. Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain1990; 113: 1597–628. · DOI
  36. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983; 13: 227–31. · DOI · Paper page
  37. Poser S, Raun NE, Poser W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta Neurol Scand1982; 66: 355–62. · DOI
  38. Poser S. Multiple sclerosis. An analysis of 812 cases by means of electronic data processing. Berlin: Springer-Verlag; 1978.
  39. Riise T, Gronning M, Fernandez O, Lauer K, Midgard R, Minderhoud JM, et al. Early prognostic factors for disability in multiple sclerosis, a European multicenter study. Acta Neurol Scand1992; 85: 212–8. · DOI
  40. Rudick R, Cohen JA, Weinstock-Guttman B, Kinkel RP, Ransohoff RM. Management of multiple sclerosis. N Engl J Med1997; 337: 1604–11. · DOI · Paper page
  41. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain1993; 116: 117–34. · DOI · Paper page
  42. Schumacher GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al. Problems of experimental trials of therapy in MS: report by the panel on the evaluation of experimental trials of therapy in MS. Ann NY Acad Sci1965; 122: 552–68. · DOI · Paper page
  43. Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci2002; 22: 2451–9. · DOI · Paper page
  44. Smith ME, Eller NL, McFarland HF, Racke MK, Raine CS. Age dependence of clinical and pathological manifestations of autoimmune demyelination. Implications for multiple sclerosis. Am J Pathol1999; 155: 1147–61. · DOI
  45. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science1996; 273: 59–63. · DOI · Paper page
  46. Trojano M, Avolio C, Manzari C, Calo A, De Robertis F, Serio G, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry1995; 58: 300–6. · DOI
  47. Trojano M, Liguori M, Bosco Zimatore G, Zimatore G, Bugarini R, Avolio C, et al. Age-related disability in multiple sclerosis. Ann Neurol2002; 51: 475–80. · DOI
  48. Visscher BR, Liu KS, Clark VA, Detels R, Malmgren RM, Dudley JP. Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol Scand1984; 70: 321–8. · DOI
  49. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci2003; 206: 135–7. · DOI
  50. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain1989; 112: 133–46. · DOI · Paper page
  51. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain1989; 112: 1419–28. · DOI · Paper page
  52. Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain1991; 114: 1045–56. · DOI · Paper page
  53. Youl BD, Turano G, Miller DH, Towell AD, MacManus DG, Moore SG, et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain1991; 114: 2437–50. · DOI · Paper page

Cited by

See all 525

Metadata

Authors
Confavreux, C., & Vukusic, S.
Venue
Brain
Publisher
Oxford University Press (OUP)
Published
2006-01-16
Volume
129
Issue
3
Pages
595-605
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
DOI
10.1093/brain/awh714
OpenAlex
W2099647077
Cited by
525
References
2
FWCI
14.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Age at disability milestones in multiple sclerosis. https://app.cochat.ai/papers/10.1093/brain/awh714
The paper
Confavreux, C., & Vukusic, S. (2006). Age at disability milestones in multiple sclerosis. Brain. https://doi.org/10.1093/brain/awh714

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.